Johnson & Johnson (NYSE:JNJ) was upgraded by equities research analysts at Vetr from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The firm presently has a $152.28 price objective on the stock. Vetr‘s price objective would indicate a potential upside of 7.37% from the company’s current price.

A number of other brokerages also recently weighed in on JNJ. Wells Fargo & Co restated an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Monday. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Citigroup boosted their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $146.01.

Shares of Johnson & Johnson (NYSE JNJ) traded down $6.31 on Tuesday, reaching $141.83. 17,449,593 shares of the company were exchanged, compared to its average volume of 6,160,000. The firm has a market capitalization of $381,030.00, a P/E ratio of 24.62, a price-to-earnings-growth ratio of 2.76 and a beta of 0.80. Johnson & Johnson has a fifty-two week low of $110.76 and a fifty-two week high of $148.32. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.58 earnings per share. analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Harding Loevner LP bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $124,000. Cerebellum GP LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $166,000. Finally, Shine Investment Advisory Services Inc. bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $177,000. 65.72% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Raised to Buy at Vetr” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-raised-to-buy-at-vetr/1820635.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.